source
- Replimune appoints former Genentech exec Michelle DiNapoli as chief commercial officer after accelerated melanoma approvalReplimune announced that Michelle DiNapoli will become its chief commercial officer, starting August 18. DiNapoli previously held senior roles at Genentech, where she led commercial operations. Th…
- New study shows focal therapy matches surgery and radiation survival while reducing side effects in localized prostate cancerPhysicians remain split over focal therapy for localized prostate cancer, a technique that targets MRI‑visible lesions with heat, cold, or other energy sources instead of removing the entire gland.…